Compare IONQ Inc (IONQ) vs Pfizer Inc (PFE) Price & Performance

IONQ trades at $41.34, down 4.5% today, with a mixed technical signal leaning bullish overall. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, reflecting high growth spending. Recent news highlights strong analyst backing, including Bank of America's Buy rating and $60 target, citing IonQ's trapped-ion quantum computing technology and partnerships.

Outlook: IonQ offers high growth potential in quantum computing, supported by bullish analyst targets averaging $62.75. Risks include persistent losses, cash burn, and intense competition. Investors should weigh the long-term disruptive potential against current profitability challenges and valuation premiums.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.